Enhanced Peptide-Based Vaccination Against Acinetobacter Baumannii

The present inventive concept relates to improved peptide-based vaccination against Acinetobacter baumannii, providing enhanced immune response, stability, and solubility through optimized amino acid sequences, novel formulations, and efficient production methods.

The original patent disclosed peptide-based vaccination against Acinetobacter baumannii, but had limitations in terms of stability, solubility, and immune response. The new inventive concept addresses these limitations by introducing optimized amino acid sequences, conjugation to nanoparticles or liposomes, and novel formulations, thereby providing a more effective and efficient vaccination approach.

The inventive concept encompasses a system for enhancing the immune response of a subject to Acinetobacter baumannii, comprising a polypeptide with an optimized amino acid sequence derived from SEQ ID NO: 27, exhibiting improved stability and solubility. Additionally, the concept includes methods for producing pharmaceutical compositions, comprising the steps of expressing polynucleotides encoding polypeptides derived from Acinetobacter baumannii in host organisms and formulating the expressed polypeptides with immunological adjuvants and pharmaceutically acceptable carriers. Furthermore, the concept involves vaccine compositions, comprising polypeptides derived from Acinetobacter baumannii conjugated to nanoparticles or liposomes, and kits for preparing pharmaceutical compositions, comprising lyophilized polypeptides and separate compartments for immunological adjuvants. The inventive concept also includes methods for treating bacterial infections caused by Acinetobacter baumannii, comprising administering pharmaceutical compositions comprising polypeptides derived from Acinetobacter baumannii, immunological adjuvants, and pharmaceutically acceptable carriers in a dose-escalating regimen.

The new inventive concept provides a significant improvement over the original patent by introducing optimized amino acid sequences, novel formulations, and efficient production methods, which are not obvious from the original patent. The inventive concept's novelty lies in the combination of these features, which provide enhanced immune response, stability, and solubility.

Alternative embodiments of the inventive concept may include varying the optimized amino acid sequence, using different nanoparticles or liposomes, or modifying the production methods. Variations may also include using different immunological adjuvants, carriers, or dosing regimens.

The inventive concept has significant commercial potential in the vaccine market, particularly in the context of antimicrobial prophylaxis and therapy. The improved peptide-based vaccination approach may be attractive to pharmaceutical companies, biotech companies, and research institutions focused on developing novel vaccination strategies against Acinetobacter baumannii and other bacterial infections.